Therapy of Angiosarcoma with Thalidomide and Lenalidomide
Angiosarcoma is an uncommon malignancy with a poor prognosis. Systemic therapy options for patients with metastatic disease generally have limited effectiveness. In this case study, a 73-year-old male with metastatic angiosarcoma who previously declined chemotherapy and developed progressive disease...
Saved in:
Main Authors: | M. Jules Mattes, Jeffrey A. Mattes, Roman Groisberg, Malcolm D. Mattes |
---|---|
Format: | article |
Language: | EN |
Published: |
Karger Publishers
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/11781034e0c34366bdad1c958c3619c5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deep Vein Thrombosis as an Initial Symptom of Malignant Tumor: A Case Report of Angiosarcoma in the Iliac Vein
by: Takahiro Matsui, et al.
Published: (2021) -
Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis
by: Jia Li, et al.
Published: (2021) -
Clinical implications of systemic and local immune responses in human angiosarcoma
by: Jason Yongsheng Chan, et al.
Published: (2021) -
Multifocal Epithelioid Hemangioendothelioma Complicated with Disseminated Intravascular Coagulation
by: Hiroaki Kimura, et al.
Published: (2021) -
Comment on Kronenfeld et al. Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable. <i>Cancers</i> 2021, <i>13</i>, 3814
by: Markus Notter, et al.
Published: (2021)